West Pharmaceutical Services
WST NYSE· Health Care Supplies
Last close · Oct 26, 2026
$394.73
KIRA · Stoqly’s AI analyst, in plain words
- West Pharmaceutical Services had $3.1B of revenue in fiscal 2025, up 6.3% on the year before. Over five years, revenue changed +7.4% a year on average.
- Its operating margin was 19.0%, down 0.7 pts: of every 100 in sales, about 19 is left after running the business.
- West Pharmaceutical Services made $494M of net profit in fiscal 2025. From fiscal 2016 to 2025, diluted EPS grew 15.1% a year.
- Free cash flow was $469M in fiscal 2025, 15.3% of revenue.
- West Pharmaceutical Services returned $195M to shareholders in fiscal 2025, 42% of free cash flow. The diluted share count fell 1.4%.
- West Pharmaceutical Services has $583M more cash than debt.
Market cap
$28.1B
P/E
50.5x
Revenue
$3.1B
Net income
$494M
Free cash flow
$469M
Operating margin
19.0%
West Pharmaceutical Services in 30 seconds · fiscal 2025
Are sales growing?
+6.3%
Yes. Sales grew 6.3% last year.
Does it make a profit?
16.1%
Yes. It keeps 16.1% of every sale as profit.
Does profit turn into cash?
15.3%
Yes. 15.3% of sales ends up as free cash.
Is debt under control?
Net cash
Yes. It has more cash than debt.
How healthy are the accounts?
9 / 9
Solid. It passes 9 of 9 health tests.
How is the share priced?
50.5x
One share costs 50.5 times its yearly profit per share. Typical for its sector: 27.9x.
What West Pharmaceutical Services does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 17, 2026
- Legal name
- WEST PHARMACEUTICAL SERVICES, INC.
- CIK
- 0000105770
West Pharmaceutical Services · WST
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $2.8B | $2.9B | $2.9B | $2.9B | $3.1B |
| Revenue growth | 31.9% | 2.0% | 2.2% | −1.9% | 6.3% |
| Gross margin | 41.5% | 39.4% | 38.3% | 34.5% | 35.9% |
| Operating margin | 26.6% | 25.4% | 22.9% | 19.7% | 19.0% |
| Net income | $662M | $586M | $593M | $493M | $494M |
| Net margin | 23.4% | 20.3% | 20.1% | 17.0% | 16.1% |
| Diluted EPS | $8.67 | $7.73 | $7.88 | $6.69 | $6.79 |
| Cash | |||||
| Cash from operations | $584M | $724M | $777M | $653M | $755M |
| Capital expenditure | $253M | $285M | $362M | $377M | $286M |
| Free cash flow | $331M | $439M | $415M | $276M | $469M |
| FCF margin | 11.7% | 15.2% | 14.1% | 9.6% | 15.3% |
| Dividends paid | $51.1M | $54.1M | $57.0M | $59.1M | $61.2M |
| Share buybacks | $137M | $203M | $438M | $561M | $134M |
| Share count change | 0.7% | −0.7% | −0.7% | −2.1% | −1.4% |
| Debt and strength | |||||
| Cash and short-term investments | $763M | $894M | $854M | $485M | $791M |
| Debt incl. finance leases | $253M | $209M | $207M | $206M | $208M |
| Shareholders' equity | $2.3B | $2.7B | $2.9B | $2.7B | $3.2B |
| Net debt / EBITDA | −0.6x | −0.8x | −0.8x | −0.4x | −0.8x |
| Current ratio | 2.9x | 3.7x | 2.9x | 2.8x | 3.0x |
| Interest coverage | 91.7x | 92.9x | 75.1x | 190.0x | 1,169.8x |
| Returns and quality | |||||
| Return on capital | 38.8% | 31.9% | 26.3% | 20.1% | 18.7% |
| Return on equity | 31.6% | 23.3% | 21.3% | 17.7% | 16.9% |
| Piotroski F-score | 7 | 6 | 5 | 5 | 9 |
| Altman Z'' | 8.7 | 9.6 | 9.5 | 9.3 | 9.3 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$6.6M
2 insiders
Of sales under plans
41%
$2.7M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
West Pharmaceutical Services · WST
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Similar companies
Each company’s latest fiscal year. Fiscal years end in different months, so periods don’t line up exactly.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score |
|---|---|---|---|---|---|---|---|
| West Pharmaceutical Services WST | $28.1B | 6.3% | 19.0% | 15.3% | 18.7% | 50.5x | 9 |
| Envista NVST | $3.9B | 8.3% | 8.0% | 8.5% | 3.2% | 40.8x | 7 |
| Dentsply Sirona XRAY | $1.8B | −3.0% | −11.5% | 2.8% | −9.9% | — | 6 |
| Align Technology ALGN | $10.9B | 0.9% | 13.5% | 12.2% | 13.3% | 26.5x | 5 |
| Cooper Companies COO | $11.8B | 5.1% | 16.7% | 10.6% | 4.3% | 20.9x | 5 |
Price compared with profit (P/E)
How many times its yearly profit per share one share costs. Higher means investors pay more for each unit of profit.
KIRA
At $394.73 a share, the company is worth $28.1B: 50.5 times its earnings of the last four quarters.
West Pharmaceutical Services grew sales faster than 3 of its 4 similar companies. Its P/E is higher than 3 of 3.
Source: SEC EDGAR XBRL filings (CIK 0000105770). Data updated October 9, 2026. For information only — not investment advice. Check the original filings before relying on any figure.